Please try another search
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Todd E. Simpson | 62 | 2014 | Independent Chairman |
Robert A. Baffi | 69 | - | Director |
Cory S. Freedland | 47 | - | Director |
Rachel L. McMinn | 51 | - | Founder, CEO & Director |
Rohan Palekar | 58 | - | Director |
Sarah B. Noonberg | 56 | - | Director |
Robert Keith Woods | 56 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review